Differential activity of cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro

Csòka, Katalin; Dhar, Sumeer; Fridborg, H; Larsson, Rolf; Nygren, Peter

doi:10.1002/(sici)1097-0142(19970315)79:6<1225::aid-cncr23>3.0.co;2-0

Cited by 25 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dose-response relations with patient samples were similar to published results using cell lines obtained after 48-hour incubations ( Figure 1E; supplemental Figure 2A-B). [23][24][25][26] In contrast, in our experiments, the viability of the nonplasma cells (normal MNCs in the cultures) was not affected, except by Cy treatment (supplemental Figure 2C). Notably, the viability of plasma cells from normal donors was not affected by anti-myeloma drugs tested at the same concentrations and time points, illustrating the preferential activity for malignant MM cells (supplemental Figure 2D).…”

Section: Development Of My-dstcontrasting

confidence: 71%

Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression

Walker¹,

VanWyngarden²,

Stevens³

et al. 2020

Blood Advances

View full text Add to dashboard Cite

The oncogenic drivers and progression factors in multiple myeloma (MM) are heterogeneous and difficult to target therapeutically. Many different MM drugs have emerged, however, that attack various phenotypic aspects of malignant plasma cells. These drugs are administered in numerous, seemingly interchangeable combinations. Although the availability of many treatment options is useful, no clinical test capable of optimizing and sequencing the treatment regimens for an individual patient is currently available. To overcome this problem, we developed a functional ex vivo approach to measure patients’ inherent and acquired drug resistance. This method, which we termed myeloma drug sensitivity testing (My-DST), uses unselected bone marrow mononuclear cells with a panel of drugs in clinical use, followed by flow cytometry to measure myeloma-specific cytotoxicity. We found that using whole bone marrow cultures helped preserve primary MM cell viability. My-DST was used to profile 55 primary samples at diagnosis or at relapse. Sensitivity or resistance to each drug was determined from the change in MM viability relative to untreated control samples. My-DST identified progressive loss of sensitivity to immunomodulatory drugs, proteasome inhibitors, and daratumumab through the disease course, mirroring the clinical development of resistance. Prospectively, patients’ ex vivo drug sensitivity to the drugs subsequently received was sensitive and specific for clinical response. In addition, treatment with <2 drugs identified as sensitive by My-DST led to inferior depth and duration of clinical response. In summary, ex vivo drug sensitivity is prognostically impactful and, with further validation, may facilitate more personalized and effective therapeutic regimens.

show abstract

Section: Development Of My-dstcontrasting

confidence: 71%

Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression

Walker¹,

VanWyngarden²,

Stevens³

et al. 2020

Blood Advances

View full text Add to dashboard Cite

show abstract

“…Cytotoxic properties of CrEL have been shown in different cell types (Csoka et al, 1997) and it has been postulated that direct perturbation of cell membrane and/or formation of reactive oxygen species by peroxidation of polyunsaturated fatty acids could contribute to this effect (Gelderblon et al, 2001). In addition to inflict direct damage to vital cell constituents such as lipids, proteins and DNA (Hensley et al, 2000), reactive oxygen species may also modulate the pattern of gene expression through functional alterations of transcription factors (Van den Berg et al, 2001).…”

Section: Introductionmentioning

confidence: 99%

Oxidative stress induced by Cremophor EL is not accompanied by changes in NF-κB activation or iNOS expression

et al. 2006

View full text Add to dashboard Cite

“…Substances with LD 50 values ranging between 1 and 5,000mg/kg of the mice's body weight was considered as practically important. The LD 50 values <1 and 5,000mg/kg were regarded as very toxic and practically not important in this study [13,14]. The LD 50 of the crude extract, and the hexane and chloroform fractions of P. bistorta were determined based on the previously described procedures [13][14][15].…”

Section: Determination Of the Median Lethal Dosage (Ld 50 )mentioning

confidence: 99%

“…The LD 50 values <1 and 5,000mg/kg were regarded as very toxic and practically not important in this study [13,14]. The LD 50 of the crude extract, and the hexane and chloroform fractions of P. bistorta were determined based on the previously described procedures [13][14][15]. Finney's method of transformation of percentage mortalities to probits and the plot of probits (in ordinate) versus log doses (in abscissa) were used to determine LD 50 [16][17][18].…”

Section: Determination Of the Median Lethal Dosage (Ld 50 )mentioning

confidence: 99%

Evaluation of the Extracts From Rhizomes of Polygonum bistorta for the Median Lethal Dosages in Swiss Albino Mice

Pillai

2021

IJT

View full text Add to dashboard Cite

Background: Polygonum bistorta has been used as a remedy for jaundice, smallpox, pimples, measles, cholera, diarrhoea, dysentery, expelling worms, insect stings and snakebites. In this study, the crude extract from P. bistorta and two fractions viz. hexane and chloroform obtained from the crude extract were studied for their median Lethal Dosages (LD50) in Swiss albino mice. Methods: Powdered rhizomes of P. bistorta was macerated with chloroform and the crude extract was dissolved in a solvent mixture of methanol/water (95:5). The mixture was then subjected to solvent-solvent partition, first with hexane followed by chloroform. The crude extract and the hexane and chloroform fractions were evaluated for their LD50 in Swiss albino mice of both sexes. Results: The LD50 of the crude extract and the hexane and chloroform fractions were determined to be 142.82, 200 and 200.17mg per kg of the mice body weight, respectively. Conclusion: The LD50 values of the crude extract and the hexane and chloroform fractions from P. bistorta were determined. The crude extract of P. bistorta had greater lethality than the hexane and chloroform fractions. This is the first report on the LD50 values of Swiss albino mice for P. bistorta.

show abstract

Differential activity of cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro

Cited by 25 publications

References 24 publications

Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression

Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression

Oxidative stress induced by Cremophor EL is not accompanied by changes in NF-κB activation or iNOS expression

Evaluation of the Extracts From Rhizomes of Polygonum bistorta for the Median Lethal Dosages in Swiss Albino Mice

Contact Info

Product

Resources

About